Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...
One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...
The other, the Federal Trade Commission, is already conducting a major investigation of pharmacy benefit managers and is suing over their pricing practices regarding insulin ... three PBMs are the ...
No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...
The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
The price of insulin has been a major flashpoint ... Drugmakers blame middlemen known as pharmacy benefit managers for high drug prices. PBMs negotiate drug prices and rebates with manufacturers ...
The other, the Federal Trade Commission, is already conducting a major investigation of pharmacy benefit managers and is suing over their pricing practices regarding insulin. She was speaking just ...
10d
Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus Monday, one of the country’s top antitrust watchdogs said her agency is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback